These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

345 related articles for article (PubMed ID: 29665657)

  • 21. JAK2-positive Philadelphia-negative myeloproliferative neoplasms.
    Sharma A; Buxi G; Marwah S; Yadav R
    Indian J Pathol Microbiol; 2011; 54(1):117-20. PubMed ID: 21393891
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Elevated expression of the EZH2 gene in CALR-mutated patients with primary myelofibrosis.
    Fan N; Tang Y; Wu Z; Guan M; Chen B; Xu X; Ma W; Xu X; Zhang X
    Ann Hematol; 2018 Jul; 97(7):1193-1208. PubMed ID: 29560522
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Is there a role for JAK inhibitors in BCR-ABL1-negative myeloproliferative neoplasms other than myelofibrosis?
    Pardanani A; Tefferi A
    Leuk Lymphoma; 2014 Dec; 55(12):2706-11. PubMed ID: 25520049
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Primary myelofibrosis: 2014 update on diagnosis, risk-stratification, and management.
    Tefferi A
    Am J Hematol; 2014 Sep; 89(9):915-25. PubMed ID: 25124313
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Triple-Negative Primary Myelofibrosis: A Bone Marrow Pathology Group Study.
    Al-Ghamdi YA; Lake J; Bagg A; Thakral B; Wang SA; Bueso-Ramos C; Masarova L; Verstovsek S; Rogers HJ; Hsi ED; Gralewski JH; Chabot-Richards D; George TI; Rets A; Hasserjian RP; Weinberg OK; Parilla M; Arber DA; Padilla O; Orazi A; Tam W
    Mod Pathol; 2023 Mar; 36(3):100016. PubMed ID: 36788093
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Analysis of CALR, JAK2 and MPL gene mutations in BCR-ABL negative myeloproliferative neoplasms].
    Ouyang Y; Qiao C; Wang J; Xiao L; Zhang S
    Zhonghua Yi Xue Za Zhi; 2015 May; 95(18):1369-73. PubMed ID: 26178351
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Calreticulin exon 9 mutations in myeloproliferative neoplasms.
    Ha JS; Kim YK
    Ann Lab Med; 2015 Jan; 35(1):22-7. PubMed ID: 25553276
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Individualizing Care for Patients With Myeloproliferative Neoplasms: Integrating Genetics, Evolving Therapies, and Patient-Specific Disease Burden.
    Mesa RA; Passamonti F
    Am Soc Clin Oncol Educ Book; 2016; 35():e324-35. PubMed ID: 27249739
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Application of an NGS-based 28-gene panel in myeloproliferative neoplasms reveals distinct mutation patterns in essential thrombocythaemia, primary myelofibrosis and polycythaemia vera.
    Delic S; Rose D; Kern W; Nadarajah N; Haferlach C; Haferlach T; Meggendorfer M
    Br J Haematol; 2016 Nov; 175(3):419-426. PubMed ID: 27447873
    [TBL] [Abstract][Full Text] [Related]  

  • 31. JAK2(V617F) allele burden discriminates essential thrombocythemia from a subset of prefibrotic-stage primary myelofibrosis.
    Hussein K; Bock O; Theophile K; von Neuhoff N; Buhr T; Schlué J; Büsche G; Kreipe H
    Exp Hematol; 2009 Oct; 37(10):1186-1193.e7. PubMed ID: 19616600
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Novel myelofibrosis treatment strategies: potential partners for combination therapies.
    Stein BL; Swords R; Hochhaus A; Giles F
    Leukemia; 2014 Nov; 28(11):2139-47. PubMed ID: 24888274
    [TBL] [Abstract][Full Text] [Related]  

  • 33. GATA1 Expression in BCR/ABL1-negative Myeloproliferative Neoplasms.
    Yang N; Park S; Cho MS; Lee M; Hong KS; Mun YC; Seong CM; Huh HJ; Huh J
    Ann Lab Med; 2018 Jul; 38(4):296-305. PubMed ID: 29611379
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of a Targeted Next-Generation Sequencing Assay to Detect Diagnostically Relevant Mutations of JAK2, CALR, and MPL in Myeloproliferative Neoplasms.
    Frawley T; O'Brien CP; Conneally E; Vandenberghe E; Percy M; Langabeer SE; Haslam K
    Genet Test Mol Biomarkers; 2018 Feb; 22(2):98-103. PubMed ID: 29323541
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Myeloproliferative neoplasms: updates on molecular pathophysiology, diagnosis and treatment strategies].
    Takenaka K
    Rinsho Ketsueki; 2016; 57(10):1944-1955. PubMed ID: 27725592
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Recent advances in understanding myelofibrosis and essential thrombocythemia.
    Vainchenker W; Constantinescu SN; Plo I
    F1000Res; 2016; 5():. PubMed ID: 27134742
    [TBL] [Abstract][Full Text] [Related]  

  • 37. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Myelofibrosis in 2019: moving beyond JAK2 inhibition.
    Schieber M; Crispino JD; Stein B
    Blood Cancer J; 2019 Sep; 9(9):74. PubMed ID: 31511492
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognosis of Primary Myelofibrosis in the Genomic Era.
    Bose P; Verstovsek S
    Clin Lymphoma Myeloma Leuk; 2016 Aug; 16 Suppl():S105-13. PubMed ID: 27521306
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Calreticulin mutation profile in Indian patients with primary myelofibrosis.
    Sazawal S; Singh N; Mahapatra M; Saxena R
    Hematology; 2015 Dec; 20(10):567-70. PubMed ID: 25959795
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.